According to Medincell's press release, Dr. Grace Kim, formerly the Chief Strategy Officer, U.S. Finance, has seen an evolution in her responsibilities. Dr. Kim will now play a central role in implementing the next steps of the company's American capital development strategy. This move comes as Medincell enters a phase of strategic growth, aiming to create sustainable value for its partners and investors.
Dr. Kim's Extensive Experience
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Dr. Grace Kim has over twenty years of experience in capital markets, corporate strategy, and investment banking. Prior to Medincell, she served as Chief Strategy Officer at Molecular Templates and CEO at SNO Bio. She also runs a biotechnology consulting firm in New York. Her academic background includes a PhD in Medicinal Chemistry and Pharmacology from the University of Florida and an MBA from the Wharton School. She is also an associate professor at Columbia University.
Medincell's Innovative Drug Development
Based in Montpellier, Medincell develops long-acting injectable drugs, combining active ingredients with its proprietary BEPO technology. In April 2023, the first treatment using this technology was approved by the FDA for schizophrenia and is distributed in the United States under the name UZEDY by Teva. Medincell states that its pipeline includes numerous drug candidates, in collaboration with major pharmaceutical companies.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
